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Summary Cis-platinum (CDDP) induces severe inhibition of cell activation and cell cycle progression in
PHA-stimulated human PBL's. Applying the novel BrdU/Hoechst flow cytometric technique for high resolu-
tion cell cycle analysis we show that CDDP induced multiple cell kinetic disturbances occur simultaneously
comprising GO/Gl-arrest, and slow down and arrest of cells in S and G2/M-phase. We investigated whether
the administration of reduced glutathione (GSH) might rescue cells from proliferative disturbances induced by
CDDP. GSH at 0.15 mg ml-' only partially restored normal cell activation and cell cycle progression.
However, at 1.5mgml-' a complete normal proliferation pattern was obtained. At the highest GSH dose
rescue from inhibition of cell activation (GO/G1-phase arrest) as well as of cell cycle progression (S- and
G2/M-phase arrest) was also present after delayed addition of GSH (1, 4 and 20 h) to CDDP treated PBL's.
In addition cell viability of CDDP exposed PBL's is restored after GSH treatment. Our in vitro experiments
give evidence that an increase of WBC found in CDDP/GSH treated patients has a real underlying cellular
physiological mechanism protecting human peripheral lymphocytes from CDDP toxicity.
The clastogenic drug CDDP is widely used as antineoplastic
agent in cancer therapy. It induces DNA-damage mainly via
DNA-strand cross-links (Lippard, 1982). However, due to its
non-selective action on normal diploid and tumour cells
CDDP induces severe side effects like nephrotoxicity and
neurotoxicity. In addition leucopenia is observed in CDDP
treated patients, although at a lower frequency in comparison
to carboplatin (Canetta et al., 1985; Mangioni et al., 1989).
The selective effect of clastogenic agents on tumour cells
can be enhanced by chemoprotection (Lazo & Bahnson,
1989; Gandara et al., 1991) of the normal diploid cells
via thiol-carrying molecules like diethyldithiocarbamate,
thiourea, thiosulfate or cysteamine (Borch et al., 1990;
Bodenner et al., 1986; Gringeri et al., 1988; Zwelling et al.,
1979; Filipski et al., 1979; Markmann et al., 1985; Pfeifle et
al., 1985; Goel et al., 1989; Shrieve & Harris, 1982). How-
ever, the therapeutic use of these chemoprotectors is limited
by their toxicity. Recent reports indicate that in vivo admini-
stration of GSH (Meister & Anderson, 1983) might protect
from CDDP induced toxic side effects without interferring
with its antineoplastic action. In addition it was found that
doses of GSH used in vivo were non-toxic as analysed by
different serum parameters of nephrotoxicity and body
weight (Zunino et al., 1983; Zunino et al., 1989; Oriana et al.,
1987; Di Re et al., 1990).
To clarify the cellular effects of CDDP and GSH we
investigated the cell kinetic effects of cell activation in GO/
GI-phase and cell cycle progression through S- and G2/M-
phases. In addition cell viability was monitored via flow
cytometry. Many data are available on the proliferation of
tumour cells or permanent cell lines treated with CDDP
(Salles et al., 1983; Kanno et al., 1985; Sorenson & Eastman,
1988; Fujikane et al., 1989). However, none of the analytical
techniques used were sufficient to reveal the cellular effects
induced at the single cell level in heterogenous responding in
vitro cell populations. In this study we used a novel BrdU/
Hoechst flow cytometric analysis to evaluate the multiple cell
kinetic effects of CDDP and GSH (Kubbies et al., 1989;
Kubbies et al., 1990a; Kubbies, 1990b). For two reasons we
have chosen normal, diploid human PBL's as in vitro model
system in this study: (1) PBL's are primarily exposed after
intravenous application of CDDP, and (2) leucopenia effects
as indicated by decreased WBC are often observed in cancer
patients after CDDP drug treatment. At the cellular levels we
show that normal proliferative functions are restored by
GSH in CDDP treated PBL's, and that the rescue effect
represents a real biological phenomenon.
Materials and methods
Cell culture
Ficoll isolated PBL's were seeded in RPMI1640 medium
supplemented with 15% FCS, 1% autologous donor serum,
and 2 x 10-5 M alpha-thioglycerol (Kubbies et al., 1990a) at
an initial density of 3 x IO' cells ml-'. The PBL's were
stimulated with 5 tg ml1 PHA (Boehringer Mannheim
GmbH, Mannheim, Germany) and harvested as indicated in
the text. For the flow cytometric BrdU/Hoechst differential
cell kinetic analysis (continuous labelling with 5-bromo-
deoxyuridine) 8 x 10-5 M BrdU and deoxycytidine were
added to the culture medium (Sigma GmbH, Taufenkirchen,
Germany). Due to light-sensitivity of the BrdU-substituted
cells, cell culture and harvest was done in the dark. CDDP
(Sigma GmbH, Taufenkirchen, Germany) and GSH (Boeh-
ringer Mannheim GmbH, Mannheim, Germany) were both
dissolved in PBS/pH 7.2, and were added to the culture
medium as indicated in the result section.
Cell kinetic BrdU/Hoechst analysis
The BrdU-substituted cells were harvested, pelleted and
frozen at - 20°C in RPMI1640/10% FCS/10% DMSO until
flow cytometric analysis of samples from different harvests.
Fluorochrome labelling was done as described previously
(Kubbies et al., 1989; Kubbies et al., 1990a; Kubbies, 1990b).
Briefly, PBL's were stained with 1.2 jg ml-' Hoechst 33258
in detergent staining buffer for 15 min at 4°C, and thereafter
ethidium bromide (Figure 1) or propidium iodide (Figure 4)
was added at a final concentration of 1.51tg ml-I for addi-
tional 15 min. The DNA-staining buffer was supplemented
with 50 U ml' RNAase A (Boehringer Mannheim GmbH,
Mannheim, Germany) to avoid RNA-labelling by ethidium
bromide or propodium iodide. Flow cytometric analysis was
within 4 h after cell staining.
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Figure 1 Cell kinetic alterations induced by CDDP and GSH in
human PBL's. BrdU/Hoechst-EB flow cytometric analysis of
PBL's 66 h after PHA stimulation showing three cell cycles due
to Hoechst fluorochrome quenching in BrdU-labelled cells. 1st,
2nd, 3rd and 4th cell cycle Gl-phases: GO/GI, G0', G1" and
G1"'. The lanes emerging from the different G0-peaks represent
the corresponding S- and G2/M-phase fractions. The peak/lane in
the lower left corner corresponds to cellular debris (dead cells).
CDDP was either given alone (panels c, e, g) or in parallel to
GSH (panels d, f, h). a, untreated control, b, 1.5mgml GSH;
c, e, g) 0.3, 1.0 and 3.0 gLg ml-' CDDP; d, f, h, 1.5 mg ml' GSH
plus 0.3, 1.0 and 3.Opgml-I CDDP.
Cell viability
Cells were taken from the cell culture without washing, and
cell viability was determined by the percentages of cells in the
intact cell cluster in the forward vs right angle scatter cluster
(Combrier et al., 1989), and via trypan blue staining.
Flow cytometric technique
The flow cytometric analysis was performed using an Ortho
Cytofluorograph 50H connected to a 2151 computer system
(Ortho Instr., Westwood, MA). The dual laser analysis of the
BrdU/Hoechst technique was done using two 5 W argon
lasers (Coherent, Palo Alto, CA). The Hoechst 33258
fluorochrome was excited with the first laser tuned at
UV/50 mW, and ethidium bromide or propidium iodide were
excited with the second laser at 488 nm/150 mW. The data
were recorded at a flow rate of 400-800 cells/second gated
on the UV-light forward/right angle scatter cluster to exclude
debris, and on the peak vs area cytogram of the ethidium
bromide or propidium iodide signals to exclude cell clumps.
Emission filters used: Hoechst 33258 (bandpass K45; Balzers
GmbH, Liechtenstein), ethidium bromide or propidium
iodide (long-pass RG630; Schott GmbH, Mainz, Germany),
UV scatter signals (UGI 1, Schott GmbH, Mainz, Germany).
The bivariate BrdU/Hoechst-PI (or EB) data were transfer-
red to a PC-computer. Cell cycle and cell cycle compartment
extraction and analysis was done using the MULTI2D prog-
ram written by P.S. Rabinovitch (commerical distributor:
Phoenix Flow Systems, CA).
Results
BrdU/Hoechst cell cycle analysis
Using classical proliferation assays most of the clastogenic
agents like mitomycin C or bleomycin show inhibition of cell
proliferation. However, applying high resolution flow
cytometric techniques (BrdU/Hoechst flow cytometry), none
of the cytotoxic agents tested exhibited a single cell cycle
disturbance but multiple cell cycle alterations. In PHA
activated human PBL's they include inhibition of cell activa-
tion (increase of GO/Gl-phase), as well as of cell cycle pro-
gression (S-, G2/M-phase and G1-phase in the 2nd, 3rd and
4th cell cycle) (Kubbies et al., 1987; Kubbies et al., 1989). As
shown in Figure 1 the BrdU/Hoechst flow cytometric analysis
displays as many as three consecutive cell cycles, and reveals
the proliferative heterogeneity of PHA-activated PBL's at a
single time-point after CDDP and GSH treatment. This is
achieved by continuous labelling of the cycling cells with
BrdU, and the different quenching effect of the DNA AT-
base pair specific Hoechst fluorochrome (Kubbies et al.,
1989). In addition, due to the knowledge of the number of
cells having divided once, twice or three times after activa-
tion, for the first time the real percentages of non-cycling and
cycling cells in different compartments can be calculated
(dilution effect of the non-cycling or slowly cycling cells by
the rapidly dividing ones). In addition to qualitative im-
provements of resolution of cell cycle kinetics the BrdU/
Hoechst analysis also shows lower variation in repeat
experiments in comparison to conventional radioactive
thymidine labelling technique (Rabinovitch, 1983).
CDDP induced cell cycle disturbances
Both processes, cell activation and cell cycle progression are
affected by CDDP. As shown in Figure 1 in the control
culture (panel a) cells moved from the 1st (G0/G1) into the
2nd (G1'), 3rd (G1") and 4th (G1"') cell cycle as indicated by
their prominent G0-phase peaks. However, the non-activated
GO/GI cell fraction increases from 31.9% (control) to 39.3%,
50.4% and 83.1% at 0.3, 1.0 and 3.0iLgml1I CDDP (panels
c, e and g). In addition to alterations of the G0/G1 fraction
there is also an increase of cells in the S- and G2/M-
populations in the 1st cell cycle (cell cycle progression com-
partments) which is paralleled by the disappearance of cells
in the 3rd G1"' phase (panel c). At lower CDDP concentra-
tions the G2/M arrest and delay is more prominent, whereas
it is maximal in S-phase at intermediate and highest CDDP
concentrations, respectively. At 3.0,gml-l CDDP there is
an almost complete inhibition of cell activation, and only
16.5% of cells proliferate into the early S-phase compartment
(Figure 1, panel g).
The quantitative data from repeat experiments of CDDP
treated PBL's are shown in Table I. It displays a significant
increase of the non-cycling G0/Gl-population from
34.3 ± 2.7% (control) to 80.3 ± 6.0% (3.0figml-' CDDP),
indicating severe inhibition of cell activation due to CDDP
(P <0.001). Table I also reveals an increase ofG2/M-fractions
from 1.4 ± 0.5% (control) to 11.8 ±1.9% (1.0 sgml-'
CDDP), and a subsequent dramatic decrease to 1.9 ± 2.4%
at the highest CDDP concentration (P <0.001). On contrary
the 1st cell cycle S-phase fractions increase continuously, and
remain at high levels even at 3.0jigml-' CDDP. S-phase and
G2/M-phase increase are indicator of severe cell cycle pro-
gression disturbances induced by CDDP in addition to cell
activation inhibition.
The prominent cellular decay lanes in Figure 1 panel c, e
and g (lower left corner, indicative of cell death) increase
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Table I Quantitative changes of cell cycle kinetics induced by CDDP and
GSH
% Cell cycle compartment
GSH (mgmlh') CDDP (#Lgmlh') GO/GI S G2/M
- - 34.3 2.7 9.0 1.3 1.4 ± 0.5
1.5 - 33.8±4.3 9.8±2.4 1.2±0.7
- 0.3 41.6 3.9 11.8 ±2.3 5.8 1.6
1.0 53.8 3.3 20.4 7.3 11.8 1.9
- 3.0 80.3 ± 6.0 17.8 ± 3.6 1.9 ± 2.4
1.5 0.3 36.0 ± 5.2 9.9 ± 2.7 1.8 ± 0.8
1.5 1.0 37.8 4.2 8.8 1.7 3.5 1.6
1.5 3.0 40.6 ± 3.2 13.2 ± 3.0 2.5 ± 0.5
In comparison with Figure 2, mean values and standard deviations are shown
only for the highest GSH concentration. For simplicity only 1st cell cycle data
(GO/GI cell activation compartment, S- and G2/M cell cycle progression
compartments) are shown. Data evaluation and analysis was performed using
the BrdU/Hoechst cell kinetic analysis (see Figure 1).
dramatically with increasing CDDP concentrations. On con-
trary only small nuclear decay lanes are present in the con-
trol culture which are due primarily to spontaneous cell
death after several rounds ofreplication (exclusively from 3rd
and 4th cycle cells). At lower concentrations of 0.3 ttg ml-I
CDDP the decay lane increases significantly from the 3rd
cycle cells, and at 1.0,ugml1' (panel e) the cellular decay lane
arises from the 1st cycle G2/M-phase and 2nd cycle GI' cell
fraction. At 3.01tg ml-' CDDP no cells are found in the 2nd
and 3rd cell cycle, and the cellular decay lane originates from
the non-cycling GO/GI and early S-phase cells (Figure 1
panel g).
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Figure 2 Changes of the cell cycle compartment distribution of
CDDP and GSH treated human PBL's 66 h after PHA stimula-
tion. The quantitative data of the 1st cell cycle compartments are
derived from experiments shown in Figure 1. The broken lines
indicate control experiments without GSH, or with CDDP only.
Open bars: GSH controls; hatched bars: GSH plus CDDP.
Cell cycle rescue effects ofGSH and cell viability
Simultaneous addition to GSH to CDDP treated PBL's com-
pletely restores the normal cell activation and cell cycle pro-
gression process. Figure 1 panel b demonstrates that the
addition of 1.5 mgml-' GSH at culture setup does not alter
the cell cycle kinetics of the PBL's (panel a). However,
comparing the proliferative patterns of CDDP exposed PBL's
with the CDDP/GSH treated cells (panels c/d, e/f and g/h) it
is obvious that the normal cell cycle pattern is restored by
exogenously added GSH. Panel h in Figure 1 shows that
even at the maximum inhibitory dose of 3.0jgml1 CDDP,
cells overcome the GO/GI and early S-phase arrest and pro-
liferate into the 2nd, 3rd and 4th cell cycle, respectively.
The quantitative data of a typical experiment from a 66 h
harvest (Figure 1) are summarised in Figure 2 for three
different GSH concentrations. For simplicity only results of
the 1st cycle are shown (GO/GI-, S- and G2/M-phases).
Figure 2 displays that at 0.015, 0.15 and 1.5 mg ml-' GSH
(open bars) the cell activation and cell cycle progression was
not significantly altered in comparison to the untreated con-
trol culture (broken lines). Panel a shows that the non-cycling
GO/GI cell fraction increases from 31.9% (control) to 39.3,
50.4 and 83.1% for the CDDP treated cells at 0.3, 1.0 and
3.0jgmm1' (broken lines). The addition of 0.015mgml-'
GSH only slightly improved GO/GI cell activation at the
highest CDDP dose. However, the rescue effect becomes
more prominent at 0.15 mgml-', and is complete at
1.5mgmlP' GSH (26.6, 32.6 and 36.4% at 0.3, 1.0 and
3.0 tgmlm' CDDP plus GSH).
The complex alterations of the S- and G2/M-phases as
indicators of cell cycle progression are shown in Figure 2
panels b and c. In comparison to the 0.3fLgmm1' CDDP
treated control culture (broken line) the percentages of S-
and G2/M cells decreased in both compartments at all GSH
concentrations tested. In the 1.0 and 3.0lugml-' CDDP
treated cultures the S- and G2/M-phase populations changed
to control levels only at 1.5 mgml1 GSH. The increase of
S-phase cells at 0.15 mgml' GSH in PBL's treated with
3.0,gml1' CDDP is due to increased recruitment of cells
from the G0/G1-population (Figure 2 panel a), and a still
incomplete rescue (e.g. slower cell cycle progression). Table I
summarises the results of several experiments, and shows no
significant difference of the proliferation pattern of S- and
G2/M cells of CDDP/GSH treated PBL's in comparison to
the control culture.
Cell killing induced by CDDP is indicated by the nuclear/
cellular decay lanes shown in Figure 1 (lower left part of the
cytograms of panels c, e and g) (Kubbies, 1990b). After addi-
tion of GSH to CDDP treated PBL's these nuclear/cellular
decay lanes are significantly decreased (panels d, f and h),
and are almost identical to the control cultures (panels a and
b). Similar data were also obtained in studies quantitating
the viable cell number characterised by its forward and right
angle scatter cluster (Combrier et al., 1989). In the 66 h
harvests there was no significant difference in the percentages
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of viable cells between the untreated and 1.5 mg ml' GSH
treated control cultures (67.8 ± 3.9 vs 71.3 ± 7.7%). At 1.0
and 3.0iLgml-' CDDP the percentages of viable cells
decreased to 46.6 ± 4.0 and 27.9 ± 4.1%, respectively. After
GSH supplementation of the culture medium of the
1.01g ml-' CDDP treated cells the viable cell fraction in-
creased to 62.0 ± 5.3% (not significant compared to control
levels). However, addition of GSH to the 3.0 jig ml-' CDDP
treated culture increases the viable cell fraction to only
51.4 ± 8.0%. Although this is a relative increase of the viable
cell population of 84% in comparison to the CDDP treated
culture, it indicates that a significant cell fraction of cycling
cells of about 16% died in the cell cycle progression compart-
ments in the 1st, 2nd and/or 3rd cell cycle (GO/Gl-phase cell
activation is not affected: see Table I).
Flow cytometric analysis is a unique technique revealing
population heterogeneity in a multiparameter fashion. How-
ever, most flow cytometers provide relative data only and
give no information about absolute cell numbers. Therefore
absolute cell counts and viable cell analysis using trypan blue
exclusion were performed in an independent series of
experiments to evaluate alterations of cell numbers after
CDDP and GSH treatment. The data summarised in Table II
show that GSH at all concentrations tested does neither
affect increase in cell number nor the number of dead cells
72 h after PHA activation. On contrary, CDDP treatment
decreases the viable cell number from initially 3 x 105 to
1.7 x 105 cells ml-', whereas in the untreated control culture
it increased to 10.5 x 105 cells ml-'. In parallel the numbers
of dead cells increased from 0.8 x 105cells ml-' in the con-
trol culture to 1.3 x 105 cells ml-'. Although even at low
GSH concentrations a slight rescue effect is evident from
CDDP toxicity (data not shown), it is most prominent at
1.5 mg ml-' GSH. The viable cells increased to 8.8 x
105cellsml-', and the number of dead cells decreased to
0.7 x I05 cells ml-'.
The relative numbers of viable cells in the trypan blue
exclusion assay are higher in comparison to the flow
cytometric PI assay. This possibly is due to the fact that in
the flow cytometric assay nuclear debris PI signals from dead
cells are more significantly recognised by fluorescence detec-
tors. In addition it is noteworthy, that both experiments
shown in Table I and Table II give evidence for a GSH
induced rescue in CDDP treated cells, however, they repre-
sent different aspects of cell proliferation: the data in Table I
show quantitative cell kinetic data re-calculated on the basis
ofcell doublings (see introductory paragraph above), whereas
cell counts of Table II display the current cell culture status.
Therefore calculation of absolute numbers of cell in different
cell cycle compartments are invalid.
Time limited exposure ofCDDP and GSH
In comparison to the continuous exposure of human PBL's
to CDDP, control experiments were performed exposing cells
only for a limited period of time. Alteration of the cell
activation process was monitored by changes of the GO/GI
cell population. As shown in Figure 3, in comparison to the
untreated control cultures (broken lines) CDDP increases the
non-cycling GO/GI population after a 1, 4, 20 h and con-
Table II Changes of absolute cell numbers of viable and dead cells
after CDDP and GSH treatment
Cell number (x 105 ml-,) GSH (mgml') CDDP (igml-') Viable Dead
- - 10.5±0.7 0.8±0.3
1.5 - 10.7 0.5 0.6 0.2
- 3.0 1.7 0.2 1.2 0.2
1.5 3.0 8.8 0.3 0.7 0.2
Human PBL's were inoculated at 3 x I05cells ml' and harvested
72 h after PHA activation. After trypan blue staining viable and
dead cell numbers were counted in a hematocytometer (data
represent mean values and SD of triplicate cultures).
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Figure 3 Changes of the non-cycling GO/GI cell fraction of
human PBL's as a function oftime limited CDDP treatment. The
cells were treated for 1, 4 or 20 h after PHA-activation, washed
twice, and reseeded into complete medium in the original culture
flasks. The open bars represent the control culture with perma-
nent CDDP treatment, and the dotted line indicates the results of
the untreated control culture. Panel a 44h, and panel b 66 h
harvest.
tinuous treatment at all CDDP concentrations tested. In the
44 h harvest (Figure 3, panel a) the non-proliferating GO/GI cell fraction increases as a function of increased exposure time. On contrary, in the 66 h harvest (Figure 3 panel b) the
GO/Gl-fractions are equally elevated over the untreated con-
trols at 0.3 fg ml-' CDDP. An exposure time dependent increase in the 66 h harvest is found at higher CDDP concen-
trations. However, even a 1 h treatment is sufficient to in-
crease the GO/G2-population from 33.0% to 47.8%
(3.0ltgml-' CDDP, panel b).
The complexity of the inhibition of cell activation and cell
cycle progression after a time limited exposure of CDDP is
also reflected by the percentages of cells in subsequent cell
cycles. In the untreated control culture the cell fraction in the
3rd cell cycle 66 h after PHA-activation corresponds to
37.5%, whereas after CDDP treatment (1.0 gg ml ') it
decreases to 31.3%, 24.3%, 7.7% and 0.7% after a 1 h, 4h, 20 h and a permanent treatment, respectively. The correspond- ing 2nd cell cycle fractions are 19.2%, and 20.1%, 30.6%, 25.6% and 16.0%. This indicates that the permanent treat-
ment induces predominantly a GO/Gl-arrest (inhibition of
cell activation) whereas at intermediate exposure times (4 to
20h) the PBL's escape this stringent GO/GI-block, and are
arrested/slowed down in the 2nd cell cycle (inhibition of cell
cycle progression).
The experimental data shown above do not formally ex-
clude the possibility of a direct chemical reaction of CDDP
and GSH in the culture medium. Therefore experiments were
performed with a time-delayed addition of GSH to CDDP
treated PBL's. The cell cycle distributions of the 66 h harvests applying the high-resolution BrdU/Hoechst flow
cytometric analysis are shown in Figure 4. In the control
culture (panel a) 38.1% of the total population remained in
the GO/Gl-phase, and most of the cells moved into the 2nd
(Gi', S', G2/M') and 3rd cell cycle (GI", S", G2-M"). In the
CDDP treated culture (3.0 igml-') most of the cells are
arrested in the GO/GI-phase, and only 14.1% moved into
early S-phase (panel b). In addition the nuclear debris signals increased significantly indicating massive cell death in the
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Figure 4 Cell kinetic effects of the time-delayed addition of exogenous GSH to CDDP treated human PBL's analysed by the high
resolution BrdU/Hoechst-PI cell cycle technique (1st cycle: GO/GI, S, G2/M; 2nd cycle: G1', S', G2/M'; 3rd cycle: GI", S",
G2/M"). Panels a and b display untreated, and CDDP treated (3.0 lig ml-') control cultures, respectively. Note missing cycling
cells in the CDDP treated control culture in panel b. Panels c, d, e, and f represent cultures treated with GSH (1.5 mg ml-')
immediately, 1, 4 and 20 h after CDDP toxification.
In Figure 4 panel c the BrdU/Hoechst pattern shows that
the immediate addition of GSH restores the normal cell
proliferative pattern. This effect is also found when GSH is
given 1 and 4 h after CDDP toxification (panel d and e). If
GSH is added as late as 20 h after CDDP treatment, most of
the cells remain still in the 1st cycle (panel f: G0/G1, S and
G2/M). However, in comparison to the CDDP treated con-
trol culture shown in panel b the PBL's have left early
S-phase, and the rescue is indicated by the fact that the cells
moved completely through the S- and G2/M-phase.
Moreover, 2.9% of the cells have divided once, and are
recognised as Gl'-phase cells by the BrdU/Hoechst flow
cytometric technique (panel f). The small number of 2nd
cycle cells in the 20 h delay experiment is due to inhibition of
PHA-induced cell activation processes by the prolonged
CDDP exposure. This results in an increased lag-phase of the
entry into the 1st cycle S-phase. However, higher percentages
of 2nd and 3rd cell cycle cells are found at later harvest times
(data not shown).
The quantitative data of the 66 h harvest are summarised
in Figure 5. In comparison to the 0.3 .g ml1- CDDP treated
culture (broken lines in panel a) at each time point the
addition of GSH decreased the non-cycling GO/Gl-fractions
(% G0/GI untreated control: 38.1) and S- and G2/M-
populations almost to control levels. The improvement of cell
proliferation due to the rescue effect increases in parallel the
percentages of cells in the 2nd and 3rd cycle. The rescue
pattern is also present at 1.0 fig ml-' CDDP (panel b). How-
ever, an incomplete rescue after a 20 h delayed addition of
GSH is shown by the slight increased S-phase population
(open bar, S-phase, panel b), which is paralleled by a smaller
increase/rescue of the 2nd/3rd cell cycle population. At
3.0 jig ml-' CDDP the PBL's are completely arrested in GO/
Gl- and early S-phase (panel c, broken lines). The rescue
effect is similar whether GSH is added immediately, 1 or 4 h
after CDDP toxification. Although the percentage of the
G0/Gl-population after a 20 h treatment decreased closely to
control levels, the S- and G2/M-phase fractions are still
increased due to prolonged lag-phase duration.
GSH/GSSG levels in medium
In order to evaluate possible alterations of concentrations of
GSH in culture medium, HPLC analysis was applied for
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Figure 5 Rescue effect of CDDP treated human PBL's after
delayed addition of GSH. Cell harvest was 66h after PHA
stimulation. The data are derived from Figure 4. GSH
(l.Smgml-') was added at culture setup, 1, 4 and 20h after
CDDP toxification. The broken lines display CDDP controls of
PBL's without GSH treatment. The data represent the percent-
ages of the GO/GI, S and G2/M phase cells in the 1st cycle, and
the sum of the 2nd and 3rd cycle compartments. Panels a, b and
c: 0.3, 1.0 and 3.0figml-' CDDP.
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quantification ofreduced and oxydised glutathione. GSH was
dissolved at different concentrations in PBS adjusted to
pH 7.2, and HPLC analysis was 1 h later. The retention time
for oxydised GSSG and reduced GSH was 8.3 and 4.7 min,
respectively. The GSH-peaks of the HPLC curves were
quantitated by integration of the peak area, and runs were
performed at 0.015, 0.15 and 1.5mgmlP' GSH. The data
revealed that 87.3, 71.4 and 60.5% of the initial concentra-
tions indicated above were present as GSH in PBS. Although
analysis was not performed in medium supplemented with
FCS, this approximation indicates the effective GSH concen-
trations in GSH supplemented RPMI-medium, and show
slightly lower values due to GSH/GSSG transition.
Discussion
Glutathione is an important multifunctional biomolecule
which is of extensive interest in cancer chemotherapy (Arrick
& Nathan, 1984; Mitchell et al., 1989; Mistry & Harrap,
1991). In animal models and clinical studies the administration
of GSH decreased nephrotoxicity and myelotoxicity (increased
WBC) induced by CDDP treatment (Zunino et al., 1983;
Zunino et al., 1989; Oriana et al., 1987; Di Re et al., 1990). We
investigated whether CDDP treated human PBL's can be pro-
tected by extracellular applied GSH in order to explain par-
tially the increased WBC observed in clinical studies (Oriana et
al., 1987; Di Re et al., 1990). Most of the CDDP related cell
kinetic studies performed used permanent cell lines as in vitro
model systems (Salles et al., 1983; Kanno et al., 1985; Soren-
son & Eastman, 1988; Fujikane et al., 1989). However, for the
investigation of severe cellular side effects induced by clasto-
gens in vivo (Canetta et al., 1985; Mangioni et al., 1989),
normal diploid cells are the more adequate cell systems.
For detailed analysis we applied a novel flow cytometric
cell kinetic analysis (BrdU/Hoechst-PI technique) that is
characterised by its vastly improved information about cell
proliferation of heterogenous cell systems (Kubbies et al.,
1987; Kubbies et al., 1989) and its much lower statistical
variation in repeat experiments (Rabinovitch, 1983). We
show that multiple cell proliferative disturbances are induced
in PBL's by CDDP. Cell activation (GO/GI) as well as cell
cycle progression (S and G2/M) are inhibited in PBL's after
PHA-activation. At lower CDDP concentrations the cell
cycle progression inhibition in S- and G2/M is more promi-
nent, whereas at higher doses the cell activation process and
early S-phase cell cycle progression are affected. The doses of
CDDP used in our experiments correspond to the range of
concentrations found in the plasma of CDDP treated animals
(Pfeifle et al., 1985; Goel et al., 1989; Sasaki et al., 1989).
Therefore similar cell kinetic disturbances might be
anticipated in in vivo activated peripheral blood cells.
Treatment of cells exposed to CDDP with exogenous
reduced GSH abolishes cell proliferative disturbances: (a) the
activation process is no longer severely affected as indicated
by normal lag-phase durations and lower percentages of
non-activated GO/GI cells, and (b) the S- and G2/M-phase
arrest and/or slow down disappeared as shown by normal
1st, 2nd and 3rd cell cycle distributions (Figure 2, Table I). A
complete rescue is observed only at the highest GSH concent-
ration of 1.5 mgml' (equivalent to 4.9 mM) which is non-
toxic to human PBL's (see also Table II for absolute cell
numbers). This is a 500-fold excess of extracellular GSH in
comparison to the highest dose of CDDP. However, this
value is comparable to intracellular GSH concentrations of 3
to 5 mM in human leukocytes (Kosover, 1978). In addition
the effective exogenous GSH concentrations applied to whole
cells in our studies is in accordance with the GSH concentra-
tion necessary to stop conversion of short-lived CDDP-
DNA-monoaduct to bifunctional adducts on isolated DNA
(Eastman, 1987). These more long-lived GSH/CDDP/DNA-
monoadducts might be inactivated by DNA-repair
mechanisms. Therefore it is conceivable that the complete
GSH rescue as late as 4 h after CDDP treatment might be
explained by molecular reaction of GSH with such short-
lived CDDP/DNA-monoadducts.
The time-delayed addition of GSH (1-20h) to CDDP
treated cells should exclude the formal possibility of a
significant direct interaction between both agents in the cul-
ture medium. As shown in Figures 4 and 5, a 1 to 4 h delay
of the addition of GSH shows a complete rescue effect.
Although a 20 h delay is still effective less PBL's are found in
the 2nd and 3rd cell cycle. This is simply due to the increased
lag-phase duration of PHA activated PBL's induced by a
20 h CDDP treatment (delay of cell activation), and due to
the washing procedure which removes the cell cycle progres-
sion factor IL-2 secreted from T-cells. It has been shown
previously that (a) maximum saturation of CDDP-DNA
adducts is in the range of4 to 8 h (Eastman, 1987; Roberts &
Friedlos, 1987), and (b) a 1 to 4 h delay ofthe administration
of cysteamine and diethyldithiocarbamate in vitro still pro-
tects cells from CDDP toxicity (Bodenner et al., 1986;
Shrieve & Harris, 1982). Our experimental results are in
accordance with these data, and demonstrate that the
CDDP/GSH rescue effect obviously represents a real
biological phenomenon.
Preliminary experiments for intracellular quantitation of
GSH using the flow cytometric monochlorobimane technique
indicate that CDDP treatment of PHA-stimulated PBL's
with extracellular GSH restores normal intracellular GSH
and protein thiol content (data not shown). Previously it has
been demonstrated that permanent human lymphoid cell
lines are not permeable to extracellular GSH (Wellner et al.,
1984). Our own experimental evidence applying BSO in
PBL's as an inhibitor of intracellular GSH synthesis also
gave no evidence for the transport of extracellular GSH into
the cells. Recent experiments suggest that glutathione ester as
cell permeant molecules might decrease lethal cis-platinum
toxicity in mice. However the effective dose was only 2- to
5-fold lower in comparison to GSH (Anderson et al., 1990).
However, GSH ester is taken up by all cells, and it remains
to be shown whether there is selective chemoprotection or
cytotoxicity on tumours or tumour cells in comparison to
normal diploid cells or tissue in vivo (Zunino et al., 1983;
Zunino et al., 1989; Oriana et al., 1987; Di Re et al., 1990).
At the present we can only suggest that increased extracel-
lular GSH levels might promote intracellular GSH-synthesis
for example via increased, normally GSH-synthesis rate-
limiting cyteine uptake, although at the present the intracel-
lular effects remain obscure at the molecular level. Flow
cytometric studies ofintracellular GSH/thiol content in single
cells applying other SH-biomolecules and inhibitors of GSH
synthesis should give further insights into cellular and
molecular pathways of the rescue from CDDP toxicity.
We thank Dr H. Prinz for GSH/GSSG quantification by HPLC
analysis, K. Bauer for technical support.
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